• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Editas Medicine (NQ: EDIT )

    5.720 -0.240 (-4.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,791,618
    Open 5.780
    Bid (Size) 5.750 (6)
    Ask (Size) 5.770 (10)
    Prev. Close 5.960
    Today's Range 5.485 - 5.910
    52wk Range 4.450 - 11.69
    Shares Outstanding 81,632,619
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
    Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders. 
    Via InvestorPlace
    3 Profitable CRISPR Stocks Earning Analysts’ Praise
    Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future. 
    Via InvestorPlace

    Performance

    YTD
    -42.69%
    -42.69%
    1 Month
    +12.82%
    +12.82%
    3 Month
    +1.96%
    +1.96%
    6 Month
    -31.99%
    -31.99%
    1 Year
    -34.40%
    -34.40%

    More News

    Read More
    The 3 Best Gene Editing Stocks to Buy in July 2024
    Via InvestorPlace
    Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
    Via InvestorPlace
    3 Gene Editing Stocks That Could Make Your Grandchildren Rich
    Via InvestorPlace
    Unveiling 5 Analyst Insights On Editas Medicine
    Via Benzinga
    The Analyst Verdict: Editas Medicine In The Eyes Of 4 Experts
    Via Benzinga
    The Latest Analyst Ratings For Editas Medicine
    Via Benzinga
    Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Overlooked and Undervalued: 3 Stocks With Jaw-Dropping Upside Potential
    Via InvestorPlace
    Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
    From Editas Medicine, Inc.
    Via GlobeNewswire
    1 Wall Street Analyst Thinks Editas Medicine Stock Is Going to $15. Is It a Buy Around $5?
    Via The Motley Fool
    EDIT Stock Earnings: Editas Medicine Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Editas Medicine Announces First Quarter 2024 Results and Business Updates
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
    From Editas Medicine, Inc.
    Via GlobeNewswire
    Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
    From Editas Medicine, Inc.
    Via GlobeNewswire
    1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
    Via The Motley Fool
    1 Beaten-Down Stock With 55% Upside, According to Wall Street
    Via The Motley Fool
    Why Editas Medicine Stock Soared as Much as 42% Higher This Week
    Via The Motley Fool
    TG Therapeutics Soars On In-Line Report; Is The Biotech Rally Buoying Shares?
    Via Investor's Business Daily
    Advance Auto Parts Reports Q4 Results, Joins B&G Foods, Vipshop, ADT And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.